5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl ]thiazolidine-2,4-dione | 97322-88-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl ]thiazolidine-2,4-dione
• 英文别名: 5-[4-(6-Acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione；5-[4-(6-Acetoxy-2,5,7,8-tetramethylchroman-2-methoxy)benzyl]2,4-thiazolidinedione；5-[4-(6-Acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione；[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] acetate
• CAS: 97322-88-8
• 化学式: C₂₆H₂₉NO₆S
• 分子量: 483.585
• InChiKey: WBOOERRGGVUMFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  溴乙酸叔丁酯 、 5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl ]thiazolidine-2,4-dione 在 sodium chloride 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 t-Butyl α-{5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2,4-dioxothiazolidin-3yl}acetate
  参考文献：
  名称：

  Thiazolidine derivatives, their preparation and use

  摘要：

  公式(I)的化合物：##STR1##（其中R.sup.1 -R.sup.7是氢或各种有机基团，n是1-10，Ar是芳香族基团，U是CH.sub.2或一个碳原子与任一相邻的碳原子双键连接，W是>CH.sub.2，>C.dbd.O，>CHOH，>C.dbd.NOH或其各种衍生物）具有降低血脂过氧化物和血糖水平以及抑制醛糖还原酶活性的能力；它们可以用于这些目的的治疗。

  公开号：

  US05104888A1
• 作为产物：
  描述：

  曲格列酮 生成 5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl ]thiazolidine-2,4-dione
  参考文献：
  名称：

  YOSHIOKA, TAKAO;KITAZAWA, EIICI;KURUMADA, TOMOYUKI;YAMAZAKI, MITSUO;HASEG+

  摘要：

  DOI：

文献信息

• Benzylidenethiazolidine derivatives and their use for the inhibition
  申请人：Sankyo Company, Limited

  公开号：US05387596A1

  公开（公告）日：1995-02-07

  Benzylidenethiazolidine compounds of formula (I): ##STR1## [in which R.sup.1, R.sup.2 and R.sup.5 are each hydrogen or alkyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, formyl, alkylcarbonyl, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl, hydroxy, alkylcarbonyloxy, formyloxy, arylcarbonyloxy, optionally substituted alkoxy or halogen; W is methylene, carbonyl or a group of formula >C.dbd.N--OV, wherein V is hydrogen, alkylcarbonyl, arylcarbonyl or optionally substituted alkyl; and n is an integer of from 1 to 3] and salts thereof have the ability to inhibit the formation of lipid peroxide in the mammalian body, and can therefore be used for the treatment of arteriosclerosis and other diseases and disorders arising from an imbalance in the lipid peroxide level. They can also be used for the preparation of the corresponding benzylthiazolidine compounds, which have a generally greater hypoglycemic activity. Processes for the preparation of these compounds of formula (I) are also provided.

  Benzylidenethiazolidine化合物的化学式（I）：##STR1##[其中R.sup.1，R.sup.2和R.sup.5分别为氢或烷基；R.sup.3和R.sup.4分别为氢、烷基、甲酰基、烷基羰基、芳基羰基、羧基、烷氧羰基、芳氧羰基、羟基、烷基羰氧基、甲酰氧基、芳基羰氧基、可选择取代的烷氧基或卤素；W为亚甲基、羰基或化学式>C.dbd.N--OV的基团，其中V为氢、烷基羰基、芳基羰基或可选择取代的烷基；n为1至3的整数]及其盐具有抑制哺乳动物体内脂质过氧化物形成的能力，因此可用于治疗动脉粥样硬化和其他因脂质过氧化物水平不平衡而引起的疾病和紊乱。它们还可用于制备相应的苯基硫代乙酰胺化合物，其通常具有更强的降糖活性。还提供了制备这些化合物（I）的方法。
• Thiazolidine derivatives, their preparation and compositions containing
  申请人：Sankyo Company Limited

  公开号：US04572912A1

  公开（公告）日：1986-02-25

  The compounds of formula (I): ##STR1## [in which: R.sup.1 and R.sup.2 are the same or different and each represents hydrogen or C.sub.1 -C.sub.5 alkyl; R.sup.3 represents hydrogen, an acyl group, a (C.sub.1 -C.sub.6 alkoxy)carbonyl group or an aralkyloxycarbonyl group; R.sup.4 and R.sup.5 are the same or different and each represents hydrogen, C.sub.1 -C.sub.5 alkyl or C.sub.1 -C.sub.5 alkoxy, or R.sup.4 and R.sup.5 together represent a C.sub.1 14 C.sub.4 alkylenedioxy group; n is 1, 2 or 3; W represents the --CH.sub.2 --, >CO or >CH--OR.sup.6 group (in which R.sup.6 represents any one of the atoms or groups defined for R.sup.3 and may be the same as or different from R.sup.3); and Y and Z are the same or different and each represents oxygen or imino] and pharmaceutically acceptable salts thereof have various valuable therapeutic effects on the blood system and may be prepared by a process which includes reacting a corresponding halopropionic acid derivative with thiourea.

  式(I)的化合物：##STR1## [其中：R.sup.1和R.sup.2相同或不同，分别代表氢或C.sub.1-C.sub.5烷基；R.sup.3代表氢，酰基，(C.sub.1-C.sub.6烷氧基)羰基或苯基甲氧基羰基；R.sup.4和R.sup.5相同或不同，分别代表氢，C.sub.1-C.sub.5烷基或C.sub.1-C.sub.5烷氧基，或R.sup.4和R.sup.5一起代表C.sub.1-C.sub.4烷二氧基基团；n为1、2或3；W代表--CH.sub.2 --、>CO或>CH--OR.sup.6基团（其中R.sup.6代表R.sup.3定义的任意一个原子或基团，并且可能与R.sup.3相同或不同）；Y和Z相同或不同，分别代表氧或亚胺基]及其药学上可接受的盐在血液系统上具有各种有价值的治疗效果，并可通过将相应的卤代丙酸衍生物与硫脲反应制备。
• Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0783888A1

  公开（公告）日：1997-07-16

  Compounds of formula (I): [where R1, R2, R4 and R5 are hydrogen or alkyl and R3 is hydrogen, alkyl or various organic groups] are effective against osteoporosis at doses at which they also effectively control diabetes.

  式(I)化合物： [其中 R1、R2、R4 和 R5 为氢或烷基，R3 为氢、烷基或各种有机基团]可有效防治骨质疏松症，其剂量也可有效控制糖尿病。
• Treatment and prophylaxis of pancreatitis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0796618A1

  公开（公告）日：1997-09-24

  Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment and prevention of pancreatitis.

  胰岛素增敏剂，尤其是噻唑烷二酮化合物，如曲格列酮，可用于治疗和预防胰腺炎。
• Preparation of benzylthiazolidine derivatives
  申请人：Sankyo Company Limited

  公开号：EP0839812A1

  公开（公告）日：1998-05-06

  A process for preparing a compound of formula (Ia): [in which R1, R2 and R5 are each hydrogen or alkyl; R3 and R4 are each hydrogen, alkyl, formyl, alkylcarbonyl, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl, hydroxy, alkylcarbonyloxy, formyloxy, arylcarbonyloxy, optionally substituted alkoxy or halogen; W is methylene, carbonyl or a group of formula >C=N-OV, in which V is hydrogen, alkylcarbonyl, arylcarbonyl or optionally substituted alkyl; and n is an integer of from 1 to 3] or a salt thereof by reduction of a compound of formula (I): or a salt thereof, in which R1 to R5, W and n are as defined above.

  一种制备式 (Ia) 化合物的工艺： [其中 R1、R2 和 R5 分别为氢或烷基；R3 和 R4 分别为氢、烷基、甲酰基、烷基羰基、芳基羰基、羧基、烷氧基羰基、芳氧基羰基、羟基、烷基羰氧基、甲酰基氧基、芳基羰氧基、任选取代的烷氧基或卤素；W 是亚甲基、羰基或式 >C=N-OV 的基团，其中 V 是氢、烷基羰基、芳基羰基或任选取代的烷基；以及 n 是 1 至 3 的整数]或通过还原式（I）化合物而得到的盐： 或其盐，其中 R1 至 R5、W 和 n 如上文所定义。